Logo image of MIRO

MIROMATRIX MEDICAL INC (MIRO) Stock Fundamental Analysis

USA - NASDAQ:MIRO - US60471P1084 - Common Stock

3.39 USD
+0.02 (+0.59%)
Last: 12/12/2023, 8:00:01 PM
3.39 USD
0 (0%)
After Hours: 12/12/2023, 8:00:01 PM
Fundamental Rating

3

Overall MIRO gets a fundamental rating of 3 out of 10. We evaluated MIRO against 57 industry peers in the Life Sciences Tools & Services industry. While MIRO seems to be doing ok healthwise, there are quite some concerns on its profitability. MIRO is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MIRO has reported negative net income.
MIRO had a negative operating cash flow in the past year.
MIRO Yearly Net Income VS EBIT VS OCF VS FCFMIRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -10M -20M -30M

1.2 Ratios

MIRO has a worse Return On Assets (-117.04%) than 95.08% of its industry peers.
The Return On Equity of MIRO (-176.38%) is worse than 88.52% of its industry peers.
Industry RankSector Rank
ROA -117.04%
ROE -176.38%
ROIC N/A
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MIRO Yearly ROA, ROE, ROICMIRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

With a Gross Margin value of 47.92%, MIRO perfoms like the industry average, outperforming 54.10% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for MIRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MIRO Yearly Profit, Operating, Gross MarginsMIRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 -10K -20K -30K -40K -50K

More info and screens

4

2. Health

2.1 Basic Checks

MIRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MIRO has more shares outstanding
MIRO has a better debt/assets ratio than last year.
MIRO Yearly Shares OutstandingMIRO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 5M 10M 15M 20M
MIRO Yearly Total Debt VS Total AssetsMIRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

MIRO has an Altman-Z score of -3.73. This is a bad value and indicates that MIRO is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.73, MIRO is doing worse than 88.52% of the companies in the same industry.
MIRO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
MIRO has a Debt to Equity ratio (0.03) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -3.73
ROIC/WACCN/A
WACC12.72%
MIRO Yearly LT Debt VS Equity VS FCFMIRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 20M -20M 40M

2.3 Liquidity

MIRO has a Current Ratio of 3.46. This indicates that MIRO is financially healthy and has no problem in meeting its short term obligations.
MIRO has a Current ratio of 3.46. This is comparable to the rest of the industry: MIRO outperforms 57.38% of its industry peers.
MIRO has a Quick Ratio of 3.46. This indicates that MIRO is financially healthy and has no problem in meeting its short term obligations.
MIRO has a better Quick ratio (3.46) than 62.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.46
Quick Ratio 3.46
MIRO Yearly Current Assets VS Current LiabilitesMIRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.99% over the past year.
Looking at the last year, MIRO shows a very strong growth in Revenue. The Revenue has grown by 3100.00%.
Measured over the past years, MIRO shows a very strong growth in Revenue. The Revenue has been growing by 56.05% on average per year.
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%

3.2 Future

MIRO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.77% yearly.
Based on estimates for the next years, MIRO will show a very strong growth in Revenue. The Revenue will grow by 490.87% on average per year.
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MIRO Yearly Revenue VS EstimatesMIRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B
MIRO Yearly EPS VS EstimatesMIRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MIRO. In the last year negative earnings were reported.
Also next year MIRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MIRO Price Earnings VS Forward Price EarningsMIRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MIRO Per share dataMIRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.41%
EPS Next 3Y7.54%

More info and screens

0

5. Dividend

5.1 Amount

MIRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIROMATRIX MEDICAL INC

NASDAQ:MIRO (12/12/2023, 8:00:01 PM)

After market: 3.39 0 (0%)

3.39

+0.02 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners22.32%
Inst Owner Change-7.87%
Ins Owners108.14%
Ins Owner Change0%
Market Cap92.95M
Revenue(TTM)960.00K
Net Income(TTM)-27410000
Analysts80
Price Target3.19 (-5.9%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.41%
Min EPS beat(2)-12.04%
Max EPS beat(2)18.86%
EPS beat(4)2
Avg EPS beat(4)3.41%
Min EPS beat(4)-12.04%
Max EPS beat(4)18.86%
EPS beat(8)3
Avg EPS beat(8)-11.37%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)180.11%
Min Revenue beat(2)180.11%
Max Revenue beat(2)180.11%
Revenue beat(4)4
Avg Revenue beat(4)6622.69%
Min Revenue beat(4)180.11%
Max Revenue beat(4)25950.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-65.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)99900%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 96.83
P/FCF N/A
P/OCF N/A
P/B 5.98
P/tB 5.98
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)-0.89
FCFYN/A
OCF(TTM)-0.89
OCFYN/A
SpS0.04
BVpS0.57
TBVpS0.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -117.04%
ROE -176.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.92%
FCFM N/A
ROA(3y)-102.22%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.83%
Cap/Sales 23.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.46
Quick Ratio 3.46
Altman-Z -3.73
F-Score3
WACC12.72%
ROIC/WACCN/A
Cap/Depr(3y)718.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)3872.75%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
EPS Next Y32.47%
EPS Next 2Y18.41%
EPS Next 3Y7.54%
EPS Next 5Y19.77%
Revenue 1Y (TTM)3100%
Revenue growth 3Y56.05%
Revenue growth 5YN/A
Sales Q2Q%0%
Revenue Next Year-6.67%
Revenue Next 2Y-5.13%
Revenue Next 3Y-3.45%
Revenue Next 5Y490.87%
EBIT growth 1Y0.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.34%
EBIT Next 3Y-21.4%
EBIT Next 5YN/A
FCF growth 1Y-135.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-139.27%
OCF growth 3YN/A
OCF growth 5YN/A

MIROMATRIX MEDICAL INC / MIRO FAQ

What is the ChartMill fundamental rating of MIROMATRIX MEDICAL INC (MIRO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MIRO.


Can you provide the valuation status for MIROMATRIX MEDICAL INC?

ChartMill assigns a valuation rating of 0 / 10 to MIROMATRIX MEDICAL INC (MIRO). This can be considered as Overvalued.


How profitable is MIROMATRIX MEDICAL INC (MIRO) stock?

MIROMATRIX MEDICAL INC (MIRO) has a profitability rating of 0 / 10.


How financially healthy is MIROMATRIX MEDICAL INC?

The financial health rating of MIROMATRIX MEDICAL INC (MIRO) is 4 / 10.


Can you provide the expected EPS growth for MIRO stock?

The Earnings per Share (EPS) of MIROMATRIX MEDICAL INC (MIRO) is expected to grow by 32.47% in the next year.